Paradigm Biocapital Advisors LP Buys 150,000 Shares of Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB)

Paradigm Biocapital Advisors LP increased its position in Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB - Free Report) by 3.7% in the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 4,236,346 shares of the company's stock after buying an additional 150,000 shares during the period. Y-mAbs Therapeutics comprises approximately 1.2% of Paradigm Biocapital Advisors LP's holdings, making the stock its 22nd largest position. Paradigm Biocapital Advisors LP owned 9.46% of Y-mAbs Therapeutics worth $33,171,000 at the end of the most recent quarter.

Other hedge funds also recently bought and sold shares of the company. KLP Kapitalforvaltning AS bought a new position in Y-mAbs Therapeutics in the 4th quarter worth $46,000. Wells Fargo & Company MN lifted its stake in Y-mAbs Therapeutics by 54.1% in the 4th quarter. Wells Fargo & Company MN now owns 17,458 shares of the company's stock worth $137,000 after purchasing an additional 6,131 shares in the last quarter. SG Americas Securities LLC lifted its stake in Y-mAbs Therapeutics by 30.7% in the 4th quarter. SG Americas Securities LLC now owns 17,729 shares of the company's stock worth $139,000 after purchasing an additional 4,163 shares in the last quarter. XTX Topco Ltd lifted its stake in Y-mAbs Therapeutics by 83.8% in the 4th quarter. XTX Topco Ltd now owns 20,768 shares of the company's stock worth $163,000 after purchasing an additional 9,468 shares in the last quarter. Finally, Principal Financial Group Inc. lifted its stake in Y-mAbs Therapeutics by 9.4% in the 4th quarter. Principal Financial Group Inc. now owns 22,197 shares of the company's stock worth $174,000 after purchasing an additional 1,903 shares in the last quarter. Institutional investors own 70.85% of the company's stock.

Analysts Set New Price Targets

Several analysts have commented on the stock. HC Wainwright decreased their price target on shares of Y-mAbs Therapeutics from $22.00 to $12.00 and set a "buy" rating on the stock in a research note on Friday, March 21st. Oppenheimer decreased their price target on shares of Y-mAbs Therapeutics from $21.00 to $20.00 and set an "outperform" rating on the stock in a research note on Wednesday. Bank of America cut shares of Y-mAbs Therapeutics from a "neutral" rating to an "underperform" rating and set a $3.00 price target on the stock. in a research note on Tuesday, April 22nd. Wedbush reiterated an "outperform" rating and issued a $23.00 price target on shares of Y-mAbs Therapeutics in a research note on Monday, March 3rd. Finally, Morgan Stanley decreased their price target on shares of Y-mAbs Therapeutics from $11.00 to $7.00 and set an "underweight" rating on the stock in a research note on Wednesday, March 5th. Two research analysts have rated the stock with a sell rating, seven have issued a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $16.70.

Insider Activity at Y-mAbs Therapeutics

In related news, insider Thomas Gad sold 10,810 shares of the company's stock in a transaction dated Friday, March 7th. The shares were sold at an average price of $5.23, for a total transaction of $56,536.30. Following the transaction, the insider now directly owns 202,721 shares in the company, valued at approximately $1,060,230.83. This represents a 5.06% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. 22.50% of the stock is currently owned by insiders.

Y-mAbs Therapeutics Stock Up 6.2%

NASDAQ:YMAB traded up $0.24 during mid-day trading on Friday, hitting $4.10. 227,355 shares of the stock traded hands, compared to its average volume of 315,698. The stock has a market capitalization of $185.64 million, a price-to-earnings ratio of -7.59 and a beta of 0.53. Y-mAbs Therapeutics, Inc. has a 52 week low of $3.55 and a 52 week high of $16.11. The firm's 50 day moving average is $4.47 and its two-hundred day moving average is $7.11.

Y-mAbs Therapeutics (NASDAQ:YMAB - Get Free Report) last issued its quarterly earnings results on Tuesday, May 13th. The company reported ($0.12) EPS for the quarter, beating the consensus estimate of ($0.22) by $0.10. The company had revenue of $20.90 million for the quarter, compared to the consensus estimate of $19.97 million. Y-mAbs Therapeutics had a negative net margin of 28.22% and a negative return on equity of 24.61%. As a group, research analysts predict that Y-mAbs Therapeutics, Inc. will post -0.65 EPS for the current year.

Y-mAbs Therapeutics Company Profile

Y-mAbs Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow.